Pavurutamab
Based on 1 publication(s) in Google Scholar
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.9%
- CAS No.: 2250292-39-6
- 분자량:105.78 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Pavurutamab
More
Biological Activity
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Human
CD3E & TNFRSF17
Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs[5].
-
Dosage:0.02, 0.2 and 2 mg/kg.
-
Administration:Intravenous injection; single dose on days 3, 8, 13.
-
Result:Reduced tumor volume.
-
Animal Model:NOD/SCID mice orthotopically transplanted with L-363 MM cells[5].
-
Dosage:0.005, 0.05 and 0.5 mg/kg.
-
Administration:Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days.
-
Result:Reduced tumor volume and increased survival.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
ELISA, FACS, Functional assay
-
Immobilized Pavurutamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC50 for this effect is 1.26 ng/mL. -
Immobilized Pavurutamab can bind Human BCMA Protein (ECD, His Tag). The EC50 for this effect is 0.194 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Pavurutamab (HY-P99814). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2250292-39-6
-
Appearance Liquid
-
분자량 105.78 kDa
-
Color Colorless to light yellow
-
SMILES
[Pavurutamab]
-
Synonyms
AMG-701
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer. [Abstract]2026 Apr 8:2026.04.02.715020. PMID: 41993528
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sheridan C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39(3):251-254. [Content Brief]
[2]. Goldsmith SR, et al. Bispecific Antibodies for the Treatment of Multiple Myeloma. Curr Hematol Malig Rep. 2022 Dec;17(6):286-297. [Content Brief]
[3]. Cho SF, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207. [Content Brief]
[5]. Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020 Sep 8;4(17):4180-4194. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)